Russia still unable to solve problem of drug shortage in domestic market

28 January 2020
russia_lake_stock_large

Russia is still unable to solve a problem of a shortage of drugs in the domestic pharmaceutical market, while the current situation may further deteriorate in 2020, according to recent statements by some local pharma analysts and producers.

According to their predictions, the shortage of drugs in the Russian market will continue to grow this year, despite the status of the country as one of the world’s largest consumers of generics.

Recent data, published by some local analytic agencies show the volume of consumption of generics among the local citizens is almost 2.5 times higher than in the European Union.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Generics